[Anticoagulant therapy in left ventricular non-compaction: when, how and why].

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Jacopo Costantino, Francesco Maria Ajmone, Enrico Maggio, Federico Ballatore, Giulia Manguso, Piera Ciaramella, Nicola Galea, Maria Alfarano, Paolo Severino, Carlo Lavalle, Carmine Dario Vizza, Cristina Chimenti
{"title":"[Anticoagulant therapy in left ventricular non-compaction: when, how and why].","authors":"Jacopo Costantino,&nbsp;Francesco Maria Ajmone,&nbsp;Enrico Maggio,&nbsp;Federico Ballatore,&nbsp;Giulia Manguso,&nbsp;Piera Ciaramella,&nbsp;Nicola Galea,&nbsp;Maria Alfarano,&nbsp;Paolo Severino,&nbsp;Carlo Lavalle,&nbsp;Carmine Dario Vizza,&nbsp;Cristina Chimenti","doi":"10.1714/4129.41229","DOIUrl":null,"url":null,"abstract":"<p><p>Left ventricular non compaction (LVNC) comprises a heterogeneous group of diseases that can cause heart failure, arrhythmias, and thromboembolic events. In particular, the prevalence of thromboembolism in patients with LVNC is relevant compared to the general population. Atrial fibrillation and left ventricular thrombosis are strong predictors and require anticoagulant treatment in primary or secondary prevention, with a significant reduction in the risk of events. Long-term oral anticoagulation can be considered in patients with LVNC associated with left ventricular systolic dysfunction and sinus rhythm. On the contrary, it is not entirely clear whether the presence of deep intertrabecular recesses that cause blood flow stagnation can itself represent a thrombogenic substrate even in the absence of ventricular dysfunction and in sinus rhythm, thus indicating the use of anticoagulation.This article addresses the open question of the indication for anticoagulant therapy in LVNC, through a review of the current evidence on thromboembolic risk stratification and the initiation of anticoagulant therapy and by proposing a flow-chart as a guide to decision-making according to the clinical picture of the patient.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"24 11","pages":"866-871"},"PeriodicalIF":0.7000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4129.41229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Left ventricular non compaction (LVNC) comprises a heterogeneous group of diseases that can cause heart failure, arrhythmias, and thromboembolic events. In particular, the prevalence of thromboembolism in patients with LVNC is relevant compared to the general population. Atrial fibrillation and left ventricular thrombosis are strong predictors and require anticoagulant treatment in primary or secondary prevention, with a significant reduction in the risk of events. Long-term oral anticoagulation can be considered in patients with LVNC associated with left ventricular systolic dysfunction and sinus rhythm. On the contrary, it is not entirely clear whether the presence of deep intertrabecular recesses that cause blood flow stagnation can itself represent a thrombogenic substrate even in the absence of ventricular dysfunction and in sinus rhythm, thus indicating the use of anticoagulation.This article addresses the open question of the indication for anticoagulant therapy in LVNC, through a review of the current evidence on thromboembolic risk stratification and the initiation of anticoagulant therapy and by proposing a flow-chart as a guide to decision-making according to the clinical picture of the patient.

[左心室不实的抗凝治疗:何时、如何以及为什么]。
左心室不实(LVNC)包括一组可导致心力衰竭、心律失常和血栓栓塞事件的异质性疾病。特别是,与普通人群相比,LVNC患者的血栓栓塞发生率是相关的。心房颤动和左心室血栓形成是强有力的预测因素,需要在一级或二级预防中进行抗凝治疗,从而显著降低事件风险。伴有左心室收缩功能障碍和窦性心律的LVNC患者可考虑长期口服抗凝治疗。相反,目前尚不完全清楚,即使在没有心室功能障碍和窦性心律的情况下,导致血流停滞的深棘突间凹陷本身是否代表血栓形成基质,从而表明使用了抗凝药物。本文通过回顾血栓栓塞风险分层和抗凝治疗开始的现有证据,并根据患者的临床情况提出流程图作为决策指南,来解决LVNC抗凝治疗适应症的悬而未决的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信